Home Tags Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies
Tag: Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies
Sorrento’s TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for...
- Novel Anti-CD38 CAR-T and Anti-CD123 CAR-T Programs Utilizing Sorrento's Fully Human Antibodies Demonstrated Strong Anti-Tumor Activity in Preclinical Models of Multiple Myeloma and Acute Myeloid Leukemia, respectively
- IND Filings Are Planned for H1...